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Abstract
The usual treatment for phenylketonuria (PKU) is a phenylalanine-restricted diet. Following this diet is challenging, and long-term adher-
ence (and hence metabolic control) is commonly poor. Patients with PKU (usually, but not exclusively, with a relatively mild form of the
disorder) who are responsive to treatment with pharmacological doses of tetrahydrobiopterin (BH4) have either lower concentrations of
blood phenylalanine or improved dietary phenylalanine tolerance. The availability of a registered formulation of BH4 (sapropterin dihy-
drochloride, Kuvanw) has raised many practical issues and new questions in the dietary management of these patients. Initially, patients
and carers must understand clearly the likely benefits (and limitations) of sapropterin therapy. A minority of patients who respond to
sapropterin are able to discontinue the phenylalanine-restricted diet completely, while others are able to relax the diet to some extent.
Care is required when altering the phenylalanine-restricted diet, as this may have unintended nutritional consequences and must be under-
taken with caution. New clinical protocols are required for managing any dietary change while maintaining control of blood phenylalanine,
ensuring adequate nutrition and preventing nutritional deficiencies, overweight or obesity. An accurate initial evaluation of pre-sapropterin
phenylalanine tolerance is essential, and the desired outcome from treatment with sapropterin (e.g. reduction in blood phenylalanine or
relaxation in diet) must also be understood by the patient and carers from the outset. Continuing education and support will be required
thereafter, with further adjustment of diet and sapropterin dosage as a young patient grows.
Key words: Phenylketonuria: Sapropterin: Phenylalanine: Nutrition: Inherited metabolic disorders
Traditionally, in phenylketonuria (PKU), a lifelong low-phenyl-
alanine diet, supplemented with a phenylalanine-free protein
substitute, has been the cornerstone of treatment. Undoubtedly,
diet is a highly successful treatment, but it does require discipline
from patients and organisational skills and commitment from
carers. Not surprisingly, the severity of the dietary intervention
renders dietary adherence an issue for some patients, and any
therapy that will help ease dietary management is welcomed.
Sapropterin dihydrochloride is the biologically active
synthetic form of tetrahydrobiopterin (BH4), the naturally
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occurring, essential cofactor for the enzyme phenylalanine
hydroxylase (PAH). Kuvanw (Merck Serono, Geneva, Switzer-
land; BioMarin Pharmaceutical, Inc., Novato, CA, USA) is
the only commercial, registered formulation of sapropterin
available for prescription (for clarity, the term, ‘sapropterin’,
refers exclusively to this commercial formulation in the pre-
sent study). Sapropterin lowers blood phenylalanine concen-
trations and improves phenylalanine tolerance in a subset of
patients with PKU and is the first pharmacological treatment
approved for this indication(1,2). It is used either as an adjunc-
tive therapy to a low-phenylalanine diet, or it may provide an
alternative to diet. PKU may be severe (little or no activity of
PAH), and when untreated, it is characterised typically by very
high blood phenylalanine concentrations; or it may be mild or
moderate (in which there is some residual activity of PAH),
and when untreated is characterised by lower blood phenyl-
alanine concentrations. Response to BH4 (including saprop-
terin) treatment is usually more pronounced in patients with
a mild or moderate PKU phenotype. Approximately 20–60 %
of patients have been shown to achieve a $30 % reduction
in blood phenylalanine concentration with sapropterin or
the previous, unregistered formulation of BH4
(1–6).
The European experience with sapropterin as an adjunct to
diet therapy is limited, and there are no agreed strategies for
its use in conjunction with diet. It may therefore be some
time before adequate knowledge and experience supports a
consensus on the use of sapropterin by all professionals in
Europe. Accordingly, it is important to begin an open debate
on the implications for PKU dietary management when
sapropterin is used as an adjunct to treatment. Therefore,
the purpose of the present review is to give practical guidance
for the optimisation of diet treatment in patients treated with
sapropterin dihydrochloride and highlight areas that require
further research.
Choosing potential patients for sapropterin therapy
Ideally, to ensure equity of treatment for patients with PKU
who require a low-phenylalanine diet, regardless of age, gen-
otype and dietary adherence, they all should be offered testing
for responsiveness to sapropterin(5). However, this is unlikely
to occur at the present time for several reasons. For example,
the high cost of the drug compared with dietary treatment is a
barrier to its use in some countries, and criteria may be
required for identifying patients at the highest priority within
the BH4-responsive patient population. Potential criteria
include the presence of psychological difficulties caused by
diet, patients considered for intervention by social services,
eating disorders or patients in a poor nutritional state(7–9).
Conversely, sapropterin treatment should not be considered
as the answer to, or a reward for, poor dietary compliance,
especially as the patient may still not comply with a less
restrictive diet after a therapeutic response to sapropterin.
Some experts only recommend testing patients with a
genotype that predicts a high likelihood of BH4-responsive
PKU(10), although genotyping of PAH alone is insufficient
to predict the degree of BH4 responsiveness in an individual
patient(2,5,11,12). However, knowledge of a genotype
conferring little or no residual activity of PAH (e.g. in a patient
homozygous for R408W) greatly reduces the likelihood of
a therapeutic response to sapropterin and may provide
useful information to guide decisions on whether to apply a
sapropterin loading test.
Sapropterin may have an important role in pregnancy in
the future(13). Although dietary phenylalanine restriction is
currently the treatment of choice in pregnant women with
PKU, the European prescribing information for sapropterin
acknowledges that sapropterin may be considered in preg-
nancy, due to the clear and proven danger to the fetus from
maternal hyperphenylalaninaemia, but ‘only if strict dietary
management does not adequately reduce blood phenylalanine
levels’. Sapropterin has been used occasionally, during
preconception and pregnancy, at low doses (50–100 mg/d
in the first trimester to 300–400 mg/d in the third trimester)(14)
and mostly in women with poor control on diet alone. Reports
of successful pregnancy outcomes, with normal infant neuro-
logical and physical development, have been published(14,15).
Pre-sapropterin patient/carer interview
It is essential to try to manage patient/carer expectations
regarding sapropterin. In particular, patients and carers must
understand the likelihood of sapropterin responsiveness and
be briefed carefully on the potential benefits of the drug. Care-
ful explanation is also required on how treatment with saprop-
terin is introduced, how its effectiveness is assessed, how diet
will be adjusted, the impact of illness on blood phenylalanine
concentrations, what monitoring will be required and the like-
lihood of its continued long-term use. In addition, the possi-
bility of an agreed patient contract can be considered, which
outlines the conditions under which sapropterin may be with-
drawn and full dietary treatment recommenced.
Pre-sapropterin dietary work-up
An unchanged daily phenylalanine allowance may have been
prescribed for years if blood phenylalanine concentrations
remain within the target range, even though an individual’s
total phenylalanine requirements may have increased as a
consequence of growth. This may be especially important in
patients with non-PKU hyperphenylalaninaemia who are not
prescribed a phenylalanine-free protein substitute, but who
may still restrict their intake of natural protein, resulting in
protein insufficiency(16). Therefore, it is important to establish
actual phenylalanine tolerance before starting sapropterin
(carers or patients should prospectively and accurately
record all sources of dietary phenylalanine over 3 d).
Knowledge of day-to-day variability in blood phenylalanine
concentrations, based on fasting blood samples, is important
when assessing sapropterin therapy. Fasting blood phenyl-
alanine concentrations should be monitored weekly for at
least 4 weeks before the sapropterin response test to give a
good indication of overall blood phenylalanine control on
diet only.
Issues with dietary treatment, e.g. hunger and adherence, as
well as nutritional status (growth, undernutrition, body fat
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composition and micronutrient status) and haematological
and biochemical nutritional intake(17) should be documented.
Sapropterin oral response test
Several protocols for BH4 loading tests for use in the diagnosis
of BH4-responsive PKU have been described, with initial
doses of 10–20 mg sapropterin/kg per d(5,18). A blood phenyl-
alanine concentration of .400mmol/l(19) at the start of the test
is generally regarded as a pragmatic compromise between a
high enough level to permit ready detection of a treatment
effect of sapropterin, while remaining reasonably close to
lower goal values for younger patients. A reduction in blood
phenylalanine of .30 % is generally regarded as a response
to treatment, although also the European prescribing
information for sapropterin recognises the freedom of the
prescribing physician to set a therapeutic blood phenylalanine
goal for an individual patient.
The rate of response to BH4 varies, and slow responders
(patients who do not respond with a substantial reduction in
blood phenylalanine within 48 h of the initiation of treatment)
make up 20–30 % of cases(9,10,20,21). The duration of the
sapropterin response test has varied from 8 h to 1 week,
with an extension to 4 weeks(5).
Adjusting the low-phenylalanine diet
The main goal of sapropterin treatment is to lower blood
phenylalanine concentrations, increase dietary phenylalanine
tolerance(22) and subsequently reduce or eliminate the need
for a phenylalanine-free protein substitute. Ultimately, the
degree of diet liberalisation will depend on the magnitude
of the change in blood phenylalanine/phenylalanine tolerance
and the target blood phenylalanine concentration.
Some patients, especially those with a milder PKU pheno-
type, may demonstrate a large and rapid decrease in blood
phenylalanine, associated with a marked increase in their
tolerance of dietary phenylalanine(23), although further evalu-
ation in randomised controlled trials is required to validate
this. Given the variable therapeutic response to sapropterin
in clinical trials, any protocol for phenylalanine introduction
should be individually determined.
A minority of patients with good phenylalanine tolerance
on sapropterin will be able to stop their natural protein restric-
tion and are likely to tolerate rapid introduction of dietary
phenylalanine(21). Most responders will still require some
dietary restriction but have a two- to threefold increase in
dietary phenylalanine intake(8,24). Any increase in dietary
intake must be carefully titrated with the measurement of
blood phenylalanine concentrations and adjustment of the
sapropterin dose, where appropriate.
A variety of protocols have been suggested for increasing
dietary phenylalanine. Lambruschini et al.(25) increased dietary
phenylalanine by 200 mg/d per week in patients with mild or
moderate PKU. Singh et al.(26) suggested an introduction of
10 mg sapropterin/kg per d, although a more conservative
introduction may be a standard additional dose of 100 mg/d,
in combination with regular monitoring of blood phenylalanine
concentrations. Dietary phenylalanine should continue to be
increased, systematically, by the same amount (i.e. 100mg/d)
every 7 d, but only until blood phenylalanine concen-
trations start to escalate beyond target blood phenylalanine
concentrations. Increasing phenylalanine by an individually
determined percentage of the original daily tolerated phenyl-
alanine intake represents an alternative option.
In order to establish accurate phenylalanine tolerance, any
additional dietary phenylalanine should only be introduced
under stable conditions. A new baseline blood phenylalanine
concentration may be attained approximately 7 d after adjust-
ing the diet, although further evidence is required to establish
whether a longer period of observation would be better. Some
patients may have a delayed increase in blood phenylalanine
concentrations, and so it may be challenging to establish
definitive phenylalanine tolerance when additional phenyl-
alanine is added too quickly. Careful dietary records should
be kept during the dietary phenylalanine introduction phase.
Source of dietary phenylalanine during the introduction
phase
Without careful attention, it is possible that an excess of diet-
ary phenylalanine may be given inadvertently during the
introduction and adjustment phase. Therefore, consideration
should be given to the type of phenylalanine source initially
introduced (i.e. animal or vegetable protein sources). If
high-protein foods are introduced, but then have to be
withdrawn, this is likely to be difficult where an individual
has become accustomed to their taste. Some dietitians initially
introduce only milk or egg protein(26,27) or even L-phenyl-
alanine powder, providing a straightforward and quantitative
approach to assessing the new phenylalanine tolerance with-
out having to calculate the phenylalanine content of variable
food sources. The use of these protein sources should aid
the patient’s ability to return to their previous dietary regimen
if necessary(18).
Once the dietary phenylalanine introduction phase is
complete, any additional dietary phenylalanine should be
tolerated indefinitely, provided the sapropterin dose is titrated
in accordance with blood phenylalanine concentrations and
adherence to drug and diet is satisfactory (the European pre-
scribing information for sapropterin states that the sapropterin
dose is ‘adjusted, usually between 5 and 20 mg/kg per d, to
achieve and maintain adequate blood phenylalanine levels
as defined by the physician’). Although it is assumed that
patients would prefer to eat all natural sources of protein,
some may be hesitant to try high-protein foods, because
they have been taught to avoid these foods in the past.
Phenylalanine-free protein substitute adjustment
Some patients may struggle with the taste and daily routine of
protein substitute and may identify a reduction in its dosage as
a goal of sapropterin treatment. Previously, few studies have
demonstrated that removal of the substitute from the diet
may be possible for half or more of BH4-treated patients
with mild or moderate PKU, including treatment periods
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measured in years(8,23,25). The following two criteria should be
met before there is any reduction in the dosage of the protein
substitute: (1) the total protein equivalent intake (from natural
sources and protein substitute) should supply, as a minimum,
the safe level of protein intake defined by the WHO(28); (2) all
vitamin and mineral requirements should be met.
In patients on dietary treatment only, protein substitute may
provide as much as 85 % of the total protein requirement. In
sapropterin-responsive patients, it is assumed that protein
equivalent from protein substitute will be exchanged, gram-
per-gram, for natural dietary protein(7). However, phenyl-
alanine-free protein substitutes have many functions in
addition to supplying non-phenylalanine essential amino
acids. They contribute to: (1) lowering of blood phenylalanine
concentrations(29–31) (probably associated with anabolism and
competition with phenylalanine for absorption from the gut);
(2) providing an important source of dietary tyrosine; (3)
providing some essential fatty acids and DHA. An alternative
approach to protein substitute administration is treatment
with large, neutral amino acid supplementation, which is
believed to reduce phenylalanine transport across the
blood–brain barrier(32,33). The influence of treatment with
sapropterin on the ratio of phenylalanine to other large, neu-
tral amino acid or the need for continued prescription of large,
neutral amino acid supplements remains to be determined.
Because of the valuable role of a protein substitute, some
experts consider that it should always be administered(26). It
may be particularly important during illness to help control
blood phenylalanine concentrations, and it is essential that
patients remain accustomed to its taste for use during illness,
pregnancy or if sapropterin treatment is stopped.
Most protein substitutes are enriched with micronutrients.
Reducing the dose, even with improved phenylalanine toler-
ance, may compromise intake of vitamins and trace minerals,
if the nutritional quality of the extra dietary phenylalanine
sources is limited. If few natural protein sources are eaten,
an additional dietary supplement of micronutrients is desir-
able. Therefore, either a separate vitamin and mineral sup-
plement should be prescribed or there may be a need for
new protein substitutes for use with sapropterin, containing
a higher concentration of vitamin and minerals relative to
phenylalanine-free protein, to compensate for a partial
withdrawal of the substitute.
Special low-protein foods
Sapropterin-responsive patients who experience a two- or
threefold increase in phenylalanine tolerance should reduce
their dependence on special low-protein foods such as
bread, biscuits and pasta, but this will be determined by over-
all phenylalanine tolerance, appetite and energy requirements.
Any reduction in the use of special low-protein foods should
save the family time because of less need for special food
preparation.
Nutritional quality of diet
Some patients accustomed to eating a low-phenylalanine diet
may still choose to eat a limited range of foods and may be at
risk of developing nutrient deficiencies if they transfer to a
normal diet without continued nutritional support with vita-
min and mineral supplementation. However, when eleven
patients were treated for 1 year with BH4, and a normal diet
was introduced and protein substitute stopped, no differences
in the nutritional marker status were observed, and all were
within target reference ranges. Interestingly, plasma levels of
Se significantly increased without any significant changes in
the daily Se intake during that year(25).
Patient/carer education
Patients/carers require education about healthy ‘normal’ nutri-
tion, diet and lifestyle if they are sapropterin responsive. They
will need information about the protein and nutritional con-
tent of higher-protein foods, the principles of weight control,
illness management and the continued need for adherence
with the new treatment regimen, and the regular monitoring
of blood phenylalanine concentrations. There have been no
reports to date describing dietary patterns, range of foods
eaten and quality of diet in BH4-responsive patients.
Monitoring
In general, monitoring during sapropterin treatment follows
the same principles as outlined in the dietary management
of PKU. Blood phenylalanine and tyrosine concentrations
should be monitored frequently during any dietary manipula-
tions due to the highly variable responses to sapropterin. Tran-
siently low blood phenylalanine concentrations (,26mmol/l)
may occur if insufficient dietary phenylalanine is given(2).
Weekly testing should be a minimum requirement during
stabilisation of diet after introducing sapropterin, although
some recommend daily testing (where laboratory support
for this is available). An assessment of diurnal variation in
blood phenylalanine is helpful, as a high intake of dietary
phenylalanine with a reduced dose of protein substitute is
likely to lead to an increase in phenylalanine concentration
during the day. Once stability in blood phenylalanine concen-
trations and dietary phenylalanine tolerance is achieved,
blood phenylalanine monitoring may be carried out according
to the local guidelines.
Reassuringly, it has been reported that tyrosine concen-
trations remain unchanged with BH4 treatment
(24,34). A
reduced variability in phenylalanine:tyrosine ratios in BH4-
responsive patients, compared with age-matched non-respon-
sive PKU patients, has also been documented(34).
Dietary intake, growth or BMI (depending on age) should
be checked at least monthly until food patterns have stabil-
ised, to ensure that all nutritional requirements are met and
normal growth or weight is achieved, followed by a return
to the usual monitoring guidelines for the age group. It is
essential that biochemical/haematological nutritional markers
be assessed annually in the long term, similar to when PKU
is treated by diet only(17). Table 1 shows a number of measure-
ments that may facilitate optimisation of nutrition, although
tests for some metabolites may be expensive, such as glutathione
A. MacDonald et al.178
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peroxidase, Zn, Se or fatty acids, and may be considered as
unessential to the routine management of PKU.
Quality of life should also be monitored: although there are
no specific assessment tools for patients with PKU, it is import-
ant to document any practical and social difficulties associated
with PKU, diet and treatment. Information on social outcome
relating to school, work, friendships and general satisfaction
with life is helpful. It is also important to monitor the impact
of sapropterin and a relaxed dietary approach on neurocogni-
tive function and quality of life. Measurements should be
assessed at baseline and then at regular intervals during
sapropterin treatment.
Potential issues with sapropterin
Growth
Impaired growth has been reported in some but not all studies
in diet-treated children with PKU(35). Longitudinal data with
BH4 treatment are limited, but a group of five infants given
sapropterin for 24 months maintained growth, length and
head circumference within the normal ranges for age and
sex(24). All had normal mental and motor development.
Weight management
While unhealthy foods may be chosen by patients prescribed
a stringent or relaxed diet, greater dietary freedom may result
in higher consumption of high-carbohydrate and fatty meals.
Overweight has been reported in children with PKU(36), and
an increase in adiposity has been reported in six of eleven
patients responsive to BH4 and eating a normal diet
(25). It is
essential to continue monitoring dietary intake and weight,
and to give appropriate dietary advice, based, if possible, on
analysis of body composition and physical activity patterns.
Illness
Blood phenylalanine typically increases with catabolic stress
(e.g. fever and trauma), and increased blood phenylalanine
has been reported in febrile sapropterin-treated or diet-treated
patients with PKU(7,23,24). It may be necessary to increase the
dose of BH4 during illness (up to a maximum dosage of
20 mg sapropterin/kg per d), to reintroduce protein substitute
or to reduce dietary phenylalanine intake temporarily(7,37).
Reintroduction of diet may be exceptionally difficult during
illness, especially for younger patients and particularly if
the patient had become accustomed to a normal diet.
Long-term management with sapropterin
There is no definition of acceptable adherence to sapropterin
and diet. Sapropterin dihydrochloride is a relatively new
treatment, and data on long-term management are limited.
A preliminary report of a long-term extension study with
sapropterin has demonstrated compliance (by tablet counting)
of .80 % in 96 % of patients (n 106) and of .60 % in 98 % of
patients (n 109); mean blood phenylalanine concentration T
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was decreased from a baseline value of 614 to 504·6 (SD 316·3)
mmol/l at 3 months and remained between 485 and 530mmol/l
thereafter(38). However, individual cases of poor adherence
have been described(4), and only 60 % of patients have
reported taking all doses correctly in another clinical trial(37).
Immediate rises in blood phenylalanine concentrations have
been described in the case of a missed dose or non-absorption
of the treatment due to vomiting(24). In principle, it might be
possible to measure sapropterin concentrations to assess
adherence to treatment. Given that lifelong treatment with
sapropterin dihydrochloride may be given to responders to
this treatment, further data on long-term efficacy and compli-
ance are required.
Fine-tuning of sapropterin dose
The individual dose of sapropterin should be adjusted as the
patient grows, within its recommended range of 5–20 mg/kg
per d.
Conclusions
In PKU, the introduction of sapropterin is a welcome alterna-
tive therapy in the management of BH4-responsive PKU.
Ideally, treatment with sapropterin would lead to acceptable
blood phenylalanine control without dietary treatment, but
this is uncommon, and sapropterin will usually be given in
combination with diet. The introduction of sapropterin raises
a number of important questions relating to its optimal thera-
peutic use (see Fig. 1 for a summary). Long-term studies are
necessary to determine nutritional adequacy, growth, body
composition, blood phenylalanine control during illness, diur-
nal blood phenylalanine variability, and changes in the quality
and variety of foods eaten. Guidance is needed about the
amount and type of natural protein that should be consumed
before protein substitute is stopped and how best to introduce
dietary phenylalanine with sapropterin. In addition, little is
known about longer-term adherence to sapropterin treatment.
Stabilise blood Phe and establish
Phe tolerance and variability
Conduct the loading test Which test?
Patients’ expectations
Frequent monitoringIdentify false
positives
Phe-free
formula
Phe
intake
Optimise dose
of sapropterin
Stop
sapropterin
Routine monitoring
Adjust sapropterin dose as
the patient grows
Educate on sapropterin
Individualise treatment
Relax or withdraw diet?
Adjustment of protein supplement
How to adjust Phe intake?
Nutrition/growth/weight
Protein sources
Adherence (diet and drug)
Impact of illness
Challenging patients
(e.g. poor metabolic control,
poor nutritional state) 
If positive
Action Key issues
Fig. 1. Summary of key actions and issues relating to combining diet and sapropterin therapy for patients with phenylketonuria. Frequent monitoring is rec-
ommended weekly. Routine monitoring is carried out according to the usual protocol employed by the clinic. Phe, phenylalanine. See text for a full discussion of
the issues summarised here.
Table 2. Summary of the recommendations
There should be an international consensus on patient selection for
sapropterin treatment, on the oral response test to sapropterin, on
monitoring of diet and biochemical parameters, and on the financial
and psychosocial impact of treatment with sapropterin and diet
Before starting sapropterin therapy, exact dietary phenylalanine
tolerance and information about day-to-day phenylalanine tolerance
should be established
Patients and carers should understand fully the therapeutic profile of
sapropterin, the likelihood of a therapeutic response and the other
possible changes to the way their disease is managed
Phenylalanine introduction protocols should be individually determined
in responders to sapropterin, as the response to the quantity and the
rate of phenylalanine introduction are variable
Dietary phenylalanine intake must be carefully titrated with blood
phenylalanine concentrations and sapropterin dose
Phenylalanine-free protein substitute when used in combination with
sapropterin helps to achieve micronutrient requirements, probably
decreases blood phenylalanine concentrations and improves dietary
phenylalanine tolerance
Total daily protein requirements must not be reduced below a safe
level during partial or total withdrawal of the phenylalanine-free
substitute
Careful documentation of blood phenylalanine and tyrosine concen-
trations, growth, nutritional status and neurocognitive function is
essential at baseline and at regular intervals throughout sapropterin
therapy
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Finally, managing patient and family expectations when the
drug is ineffective is challenging (see Table 2 for a summary
of the recommendations).
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